{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.2","upperLimit":"77.5","value":"50.0"},{"groupId":"OG001","lowerLimit":"17.2","upperLimit":"83.7","value":"57.1"},{"groupId":"OG002","lowerLimit":"28.4","upperLimit":"78.0","value":"57.1"},{"groupId":"OG003","lowerLimit":"35.3","upperLimit":"66.6","value":"52.2"},{"groupId":"OG004","lowerLimit":"36.3","upperLimit":"69.6","value":"54.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"33"}],"units":"Participants"}],"description":"Progression-free survival is defined as the state of being alive without progression of disease. A failure is the first of the following: local progression, regional progression, distant metastasis, or death. Progression-free survival was assessed at the maximum tolerated dose using the Kaplan-Meier method to estimate the 2-year survival rate. Arms were not compared/tested.","dispersionType":"95% Confidence Interval","groups":[{"description":"SBRT delivered in 5 fractions of 10.5 Gy/fraction over 1.5 to 2 weeks for a total of 52.5 Gy","id":"OG000","title":"Level 5: 10.0 Gy/FX"},{"description":"SBRT delivered in 5 fractions of 10.5 Gy/fraction over 1.5 to 2 weeks for a total of 52.5 Gy","id":"OG001","title":"Level 6: 10.5 Gy/FX"},{"description":"SBRT delivered in 5 fractions of 11.0 Gy/fraction over 1.5 to 2 weeks for a total of 55.0 Gy","id":"OG002","title":"Level 7: 11.0 Gy/FX"},{"description":"SBRT 57.5 Gy\n\nSBRT delivered in 5 fractions of 11.5 Gy/fraction over 1.5 to 2 weeks for a total of 57.5 Gy","id":"OG003","title":"Level 8: 11.5 Gy/FX"},{"description":"SBRT 60.0 Gy\n\nSBRT delivered in 5 fractions of 12.0 Gy/fraction over 1.5 to 2 weeks for a total of 60.0 Gy","id":"OG004","title":"Level 9: 12.0 Gy/FX"}],"paramType":"NUMBER","populationDescription":"All eligible patients who started study treatment","reportingStatus":"POSTED","timeFrame":"From randomization to date of death, failure (local, regional or distant) or last follow-up. Analysis occurs after all patients have been potentially followed for 24 months, approximately 7.5 years from the start of the study.","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}